FM Protocols
Mold Illness Brain Fog: What's Happening and How to Treat It
CIRS-driven brain fog is neuroinflammation — not depression, not anxiety, not early dementia. This practitioner guide covers the neurobiology behind mold illness cognitive impairment and the sequential treatment approach that actually works.
Mold Illness Brain Fog: What's Happening and How to Treat It
The patient sitting across from you has been through a psychiatric workup. They've tried two antidepressants. They had a neuropsychological evaluation that came back with a vague label — "mild cognitive impairment, likely anxiety-related." They've been told their brain MRI is normal.
They describe their brain as "wrapped in cotton." Word retrieval fails mid-sentence. They read the same paragraph four times and can't hold it. They used to be sharp. They're not anymore.
In my experience, when this presentation includes fatigue, multi-system symptoms, and a history that involves living or working in a water-damaged building — this is not depression. This is CIRS brain fog. And it won't respond to SSRIs because the root cause isn't a serotonin deficit. It's neuroinflammation driven by biotoxin-mediated blood-brain barrier compromise.
Here's what's actually happening — and what treats it.
The Neurobiology: Why Biotoxins Affect the Brain
Understanding the mechanism matters. It helps you explain this to patients, and it helps you select interventions in the right sequence.
MMP-9 and the Blood-Brain Barrier
The central driver of CIRS brain fog is MMP-9 elevation. Matrix Metallopeptidase-9 is an enzyme produced in the setting of innate immune activation. In CIRS, chronically elevated MMP-9 degrades the tight junctions of the blood-brain barrier. [PMID 35353713]
Once those tight junctions are compromised, biotoxins, inflammatory cytokines, and activated immune mediators gain access to the CNS. The brain is no longer protected. Neuroinflammation follows. And neuroinflammation produces exactly the symptom cluster these patients describe: word-finding difficulty, processing speed impairment, memory disruption, disorientation.
MSH Suppression and Endorphin Depletion
Melanocyte Stimulating Hormone is a regulatory neuropeptide governing immune regulation, sleep architecture, pain modulation, gut motility, and endorphin production. In CIRS, the biotoxin-cytokine cascade suppresses MSH. [Shoemaker Protocol; survivingmold.com]
Low MSH means reduced endorphin production. That translates to pain amplification, non-restorative sleep, and cognitive impairment. The nightmares patients describe — vivid, disturbing, every night — are a low-MSH pattern. So is the unusual pain that doesn't fit any anatomical distribution.
VIP Depletion
Vasoactive Intestinal Polypeptide sits further downstream. It governs neuronal signaling, gut-brain axis function, and pulmonary regulation. Chronic CIRS depletes VIP over time. [Shoemaker Protocol; survivingmold.com] Low VIP patients are the ones who are still significantly impaired — cognitive and otherwise — even after the early protocol steps have made progress on C4a and MMP-9.
The Kynurenine Pathway
This mechanism often gets less attention in the CIRS literature, but it's worth understanding. Neuroinflammation activates indoleamine 2,3-dioxygenase (IDO) — shunting tryptophan down the kynurenine pathway rather than toward serotonin synthesis. [PMID 35353713] The result: less serotonin and dopamine precursor availability. This is why these patients look depressed on symptom questionnaires. This is why antidepressants provide marginal, inconsistent benefit. You're trying to top off a reservoir that has a large hole in it.
Close the hole first.
Why Brain Fog Persists After Mold Removal
This is one of the most common questions I field from patients — and from practitioners new to CIRS.
"I moved out of the moldy house six months ago. Why am I still foggy?"
Removing the exposure stops ongoing biotoxin input. It does not resolve the inflammatory cascade already in motion. MSH suppression persists months after exposure ends unless actively treated. The inflammatory markers — C4a, TGF-beta-1, MMP-9 — don't normalize on their own. They require intervention. [PMC11623837]
And if MARCoNS is present, removal alone is never enough.
MARCoNS — Multiple Antibiotic Resistant Coagulase Negative Staphylococci — is a nasal colonizer found in a significant percentage of CIRS patients. These bacteria produce exotoxins that directly suppress MSH through the nasal-CNS axis. [Shoemaker Protocol; survivingmold.com] As long as MARCoNS persists, MSH cannot recover. Cognitive symptoms driven by low MSH will not improve. Full stop.
This is why patients who do everything right — leave the building, clean up their diet, take every supplement — still feel terrible. The MARCoNS nasal culture is not optional. It changes management.
Clinical Assessment: The Cognitive Symptom Cluster
When I'm evaluating a patient for CIRS-driven brain fog, I'm looking for this specific cluster. Not just cognitive complaints — the full pattern. [Shoemaker Protocol; survivingmold.com]
Cognitive: Word-finding difficulty in mid-conversation. Short-term memory loss — "I walked into the room and have no idea why." Difficulty holding multiple thoughts simultaneously. Math errors they wouldn't have made before. Slowed processing speed.
Perceptual: Visual contrast sensitivity loss — often the first to appear and measurable with the free VCS test. Colors may look washed out. They lose their place reading. Depth perception changes.
Sleep and Pain: Non-restorative sleep regardless of hours. Vivid nightmares. Morning stiffness. Unusual, non-anatomic pain patterns. These are low-endorphin, low-MSH symptoms.
Autonomic: Excessive thirst, frequent urination, static shock. These are ADH/osmolality dysregulation patterns — part of the same cascade.
The pattern across these domains — not any single symptom — is what distinguishes CIRS brain fog from primary depression, anxiety, or cognitive decline. A patient with depression typically doesn't have light sensitivity, static shock, and unusual pain alongside their mood symptoms.
The Lab Pattern Behind CIRS Brain Fog
Four biomarkers define the neurological picture of CIRS. [PMC11623837]
MMP-9 — Elevated (above 332 ng/mL). This is the BBB compromise marker. When MMP-9 is high, biotoxins are accessing the CNS.
MSH — Low (below 35 pg/mL). This is the endorphin, sleep, and immune regulation marker. Low MSH explains the pain, sleep disruption, and cognitive symptoms that antidepressants don't fix.
TGF-beta-1 — Elevated (above 2,380 pg/mL). Drives neuroinflammation and, through its downstream effects, contributes to autoimmune component in some patients.
VIP — Low (below 23 pg/mL). The late-stage neurological marker. If VIP is low, the patient is likely in an advanced or prolonged CIRS state. VIP normalization is the goal of the final treatment step and does not happen quickly.
When I see this combination — elevated MMP-9, low MSH, elevated TGF-beta-1, low VIP — I know why the patient is cognitively impaired. I also know what the recovery arc looks like: months, not weeks.
Treatment: What Actually Works (and in What Order)
Sequence matters. This is not a supplement protocol. It's a sequential intervention model where each step depends on the prior one. [PMC11623837]
Step 0: Remove the Exposure
I'll say it plainly: nothing works in ongoing exposure. Not binders, not VIP, not anything. If the patient is still in the water-damaged building — living, working, or spending significant time there — treatment is futile. This is the single most important clinical decision you make with these patients.
Get an ERMI or HERTSMI-2 score. If the building is contaminated and can't be remediated, the patient needs to leave it. I know that's disruptive. It's also necessary.
Biotoxin Binding: CSM or Welchol
Once the patient is out of exposure, cholestyramine (CSM) or Welchol reduces systemic biotoxin load by sequestering biotoxins in the gut and blocking enterohepatic recirculation. [PMC11623837] CSM is more potent. Welchol is better tolerated for patients with GI sensitivity. Gluten-free formulations matter — mold-susceptible patients often have elevated anti-gliadin antibodies.
Activated charcoal and bentonite clay can augment binding in more severe cases.
MARCoNS Eradication
After the initial binder phase, culture the nasal passages for MARCoNS (send to Microbiology DX). If positive — and many are — BEG spray (Bacitracin-EDTA-Gentamicin) intranasal for 30 days. Confirm eradication with repeat culture before moving forward.
This step is where a lot of cognitive improvement happens. In my practice, patients who have been "stuck" despite doing everything else often turn a corner after MARCoNS eradication. MSH starts to recover when it's no longer being actively suppressed.
Diet: Low-Amylose
Amylose, a specific type of starch found in rice, corn, and potatoes, appears to provide inflammatory fuel in CIRS patients. The low-amylose diet is standard Shoemaker protocol and has real clinical impact. [Shoemaker Protocol; survivingmold.com] Think modified paleo: non-starchy vegetables, quality proteins, healthy fats. For cognitively impaired patients, dietary quality also affects neurotransmitter precursor availability.
Phospholipid Support
For patients with significant neurological and cognitive involvement, phosphatidylcholine — either oral or IV — supports membrane integrity and neuroprotection. The BBB compromise in CIRS involves membrane-level structural damage. Phospholipid support addresses that directly. [PMC8619365]
Glutathione and Antioxidant Support
Mycotoxins generate significant oxidative stress. Trichothecenes and ochratoxin A in particular are documented generators of reactive oxygen species. [PMC8619365] Intravenous glutathione, combined with NAC, addresses the oxidative burden that is partially driving ongoing neuroinflammation. I use this regularly in patients with severe cognitive symptoms.
VIP Restoration
Vasoactive Intestinal Polypeptide compounded nasal spray is the final and most powerful tool for neurological recovery in CIRS. It is also the one that fails — or causes adverse effects — if introduced too early. [Shoemaker Protocol; survivingmold.com]
VIP should only be introduced after:
- Exposure is eliminated
- Binders have reduced systemic biotoxin load
- MARCoNS is eradicated
- Prior protocol steps are complete
Introduce VIP with ongoing MARCoNS and you're accelerating a futile cycle. VIP in a patient who still has biotoxin burden will not restore function — the VIP will be consumed by the ongoing inflammatory cascade.
When VIP is introduced at the right time, the clinical impact can be significant: improved cognitive clarity, better sleep, reduced fatigue, improved pulmonary function.
Realistic Recovery Timeline
Set patient expectations clearly. Here's what I tell them.
Cognitive improvement tracks with biomarker normalization, and biomarker normalization happens in sequence. C4a and MMP-9 typically improve first — often within the first few months of binder therapy and MARCoNS eradication. MSH takes longer. VIP is last.
Average CIRS recovery with proper protocol: 6 to 18 months. [PMC11623837] That's a wide range because CIRS severity, duration before treatment, ongoing exposure risk, and genetic factors all affect trajectory.
In my practice, I use this language with patients: "You won't feel 100% better in a month. But we'll be checking your labs every 60-90 days, and you should see measurable improvements — both in how you feel and in what the biomarkers show. Progress is real. It just takes time."
Patients who have been sick for years sometimes take longer. Patients caught early, with lower initial biotoxin burden, can move faster. The honest answer is: it depends. What I can tell them is that the protocol has documented clinical efficacy, and when we follow it correctly, most patients improve. [PMC11623837]
Tracking CIRS Patients with HANS
Managing CIRS brain fog patients means tracking cognitive symptom clusters, biomarker trends, and protocol progression across 6-18 months of care. Each visit involves comparing current labs to prior labs, documenting protocol step, and writing notes that reflect complex clinical reasoning.
HANS is designed for exactly this kind of longitudinal complexity. You can track symptom changes visit-to-visit, flag lab trends across the C4a/MMP-9/MSH/VIP panel, and generate notes that document your protocol thinking without rebuilding the documentation each time. For a condition where documentation rigor matters this much, it reduces the burden significantly.
The Cognitive Improvement Patients Don't Expect
Here's what I've found: the cognitive recovery in CIRS patients — when it happens — often surprises them. These aren't patients who were born with cognitive limitations. They were functioning adults who got sick. When the neuroinflammation resolves, when MMP-9 comes down and MSH recovers, they get their brain back.
That's the outcome worth working toward. The protocol is demanding. The documentation is intensive. The patient education takes time. But these patients have usually been suffering for years before they find their way to a practitioner who can actually help.
When you're the one who figures it out — that matters.
Related Articles in This Series
- Mold Illness & CIRS: The Complete Functional Medicine Guide — full clinical overview
- CIRS Lab Testing Guide: Interpreting Shoemaker Biomarkers — panel selection, reference ranges, interpretation sequence
- Shoemaker Protocol: Step-by-Step FM Implementation — full 16-step protocol walkthrough
Peter Kozlowski, MD is a functional medicine physician and clinical educator. This content is intended for licensed medical practitioners.